In­cyte takes a beat­ing as a key PhI­II study flops in their lat­est painful set­back — block­buster hopes crushed

An­oth­er late-stage cat­a­lyst at In­cyte is go­ing down in flames.

Wide­ly viewed as a key mo­ment for In­cyte, which has been work­ing to make a come­back af­ter the IDO dis­as­ter with epaca­do­stat, the biotech re­port­ed Thurs­day evening that its Phase III study for itac­i­tinib in first-line graft vs host dis­ease has flopped.

Shares $IN­CY tanked 10% on the news af­ter the bell, nick­ing off close to $2 bil­lion in mar­ket cap.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER